ALISO VIEJO, Calif.—Visionary Ventures, an Orange County California based venture capital firm, yesterday announced the closing of Visionary Venture Fund II with $114 million in committed capital. The fund, which was strongly supported by existing and new investors, continues the firm’s strategy of partnering with ophthalmology and optometry key opinion leader (KOL) limited partners to invest in ophthalmic pharmaceuticals and medical devices. Fund II enjoys investment and input from over 80 KOL experts spanning the front and back of the eye, according to Visionary Ventures.

Visionary Ventures reported that it has experienced strong momentum recently with the performance of its investments and the most recent raise of the second fund. A recent public offering from its Fund II portfolio include Tarsus Pharmaceuticals. Recent Fund II investments include leading a $30 million Series C round in a pharmaceutical product startup Orasis Pharmaceuticals that is addressing a market greater than 120 million U.S. people with presbyopia and leading a $25 million Series B round in a pharmaceutical product startup TearClear that is disrupting the way topical medications are delivered to the ocular surface. Past marquee Visionary investments include IanTech, RxSight, and Tear Film Innovations.

Leading Visionary Fund II will be managing partner, Jeffry Weinhuff and principal, Garrett Hamontree along with venture partner Daniel Gil, PhD. Visionary is supported by industry leaders on the investment advisory committee, including Richard Lindstrom, MD; Ehsan Sadri, MD; Farrell Tyson, MD; Bill Carpou; Robert Avery, MD; and Jeffry Weinhuff.